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ABSTRACT 
Lung disease is the main cause of morbidity and mortality in cystic fibrosis (CF) and 
involves chronic infection and perturbed immune responses. Tissue damage is 
mediated mostly by extracellular proteases, but other cellular proteins may also 
contribute to damage through their effect on cell activities and/or release into sputum 
fluid by means of active secretion or cell death.  
We employed Multidimensional Protein Identification Technology to identify sputum 
cellular proteins with consistently altered abundance in adults with CF, chronically 
infected with Pseudomonas aeruginosa, compared to healthy controls. Ingenuity 
Pathway Analysis, Gene Ontology, protein abundance and correlation with lung 
function were used to infer their potential clinical significance.  
Differentially abundant proteins relate to Rho family small GTPase activity, immune 
cell movement/activation, generation of reactive oxygen species and dysregulation of 
cell death and proliferation. Compositional breakdown identified high abundance of 
proteins previously associated with neutrophil extracellular traps. Furthermore, 
negative correlations with lung function were detected for 17 proteins, many of which 
have previously been associated with lung injury.  
These findings expand current understanding of the mechanisms driving CF lung 
disease and identify sputum cellular proteins with potential for use as indicators of 
disease status/prognosis, stratification determinants for treatment prescription or as 
therapeutic targets.  
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INTRODUCTION 
The lack or reduced presence at cell surfaces of fully functional cystic fibrosis 
conductance regulator (CFTR) in people with cystic fibrosis (CF) results in a build-up 
of dense, dehydrated mucus that promotes infection and thus, chronic inflammation 
[1]. Additionally, CF has been labeled a mucosal immunodeficiency syndrome 
because of the direct proinflammatory effects of CFTR dysfunction on the 
dysregulation of epithelial innate immunity and airway leukocytes [2]. As such, the 
pathophysiology of the CF lung is highly complex, involving numerous interactions 
between multiple human cell types and a diverse microbiota [3-5], as well as the 
inherent impairment of several cell types.  
Proteomic studies of the CF airways have investigated protein abundance in 
epithelial cells cultured in vitro or obtained from animal models or clinical samples [6-
13]. Furthermore, several studies have assessed the extracellular proteomes of CF 
sputum, bronchoalveolar lavage fluid (BALF) and bronchial epithelial cell secretions 
[14-19]. The main observations of these studies are summarised in the online 
supplement (Table E1). Although these studies have all contributed to our 
understanding of CF, investigations of single cell types, in vitro cultures and animal 
models have limited relevance to in situ CF lung pathogenesis. To date, the 
contribution of the global proteome of all cell types in the proportions occurring 
naturally in CF sputum has not been investigated. We hypothesized that proteins 
detected in sputum cells can have a detrimental effect on CF lung health, both 
through their effect on cell functioning and activities, and through their release into 
extracellular sputum fluid by means of active secretion or cell death. 
We employed quantitative comparative proteomics to characterise the global activity 
and protein composition of cells in CF sputum from adults chronically infected with P. 
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aeruginosa to provide insight into potential mechanisms of lung disease and to 
identify candidate biomarkers associated with poor lung function in this population. 
By employing these methods we were able to identify, in clinical samples, novel 
cellular proteins and activities likely to be clinically relevant as mechanisms for tissue 
damage and disease progression.  
 
METHODS 
Study participants 
Twelve adults with CF, aged 26.8 ± 5.98 (mean ± SD; range 18-37) were recruited at 
Belfast City Hospital on admission for treatment with intravenous antibiotics for an 
acute pulmonary exacerbation as defined by Fuchs et al. [21]. Seven were male and 
five female. All were chronically infected with P. aeruginosa. Their characteristics 
and treatment regimens are recorded in Table 1 and Table E2 (online supplement), 
respectively. Three induced sputum samples were collected from each CF 
participant at times of differing clinical status – untreated pulmonary exacerbation, 
within 24h of completing intravenous antibiotic treatment of exacerbation and 4-15 
weeks after completion of treatment. Lung function was measured as FEV1 % 
predicted prior to each sputum collection. Twelve non-smoking, healthy control 
participants, aged 29.6 ± 4.27 (mean ± SD; range 25-39) were recruited. Eight were 
female and four male. A single induced sputum sample was collected from each 
control individual. Ethical approval for this study was granted by the Office for 
Research Ethics Committees Northern Ireland (Ref: 09/NIR02/68) and informed 
consent was obtained from all subjects. 
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Age M/F PEx (previous 12 months) % FEV1 CFTR Genotype 
CF1 23 F 2 35-36 F508del/ F508del 
CF2 36 F 0 26-36 F508del/ F508del 
CF3 31 M 1 81-102 F508del/G551D 
CF4 18 M 1 57-69 F508del/ F508del 
CF5 25 M 2 52-60 F508del/ F508del 
CF6 37 F 0 51-62 F508del/ F508del 
CF7 28 M 0 26-30 F508del/ F508del 
CF11 29 F 1 49-75 F508del/ F508del 
CF12 22 M 2 31-41 F508del/ F508del 
CF13 19 M 1 55-77 F508del/ F508del 
CF15 28 F 1 73-98 F508del/R117H 
CF16 26 M 1 40-54 F508del/ F508del 
 
Table 1: Characteristics of the CF cohort. % FEV1 records the range measured over 
the 3 sputum collections. 
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Sample preparation 
For each sputum sample the cell population was harvested from mucus plugs, 
washed and proteins extracted. Briefly, approximately 1g of mucus plug was 
homogenised thoroughly with 9 ml sterile phosphate buffered saline and the cells 
pelleted by centrifugation. Following two further wash steps and cell straining to 
remove clumps, the cells were pelleted to remove all traces of supernatant. The 
pellet was then homogenised thoroughly in lysis buffer and subjected to repeated 
freeze-thaw and water bath sonication to ensure cell lysis. Insoluble debris was 
removed by centrifugation. All work was carried out at 4⁰C and in the presence of a 
protease inhibitor cocktail. Full method details are given in the online supplement. 
Proteomic methods 
Protein digestion and iTRAQ labelling were performed as described previously {{904 
Scuoppo,C. 2012}} and details are recorded in the online data supplement. Protein 
digestion with trypsin and labelling with 8plex iTRAQ Reagents (AB Sciex) were 
performed as described previously [22]. Six test samples and a reference sample 
were mixed for simultaneous analysis by 2D liquid chromatography MudPIT on line 
with an LTQ Orbitrap Velos (Thermo Electron) as described previously [22]. Further 
details of the methods employed for MudPIT are recorded in the online data 
supplement. 
Protein identification 
Peaklists were generated by Mascot Distiller and protein identification was 
performed by the Mascot search engine against the UniProt database plus NCBI 
non-redundant database, taxonomy P. aeruginosa. Further details of the methods 
used in protein identification are recorded in the online data supplement. The mass 
spectrometry proteomics data have been deposited to the ProteomeXchange 
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Consortium [23] via the PRIDE partner repository with the dataset 
identifier PXD001985 and 10.6019/PXD001985. Western immunoblot and enzyme-
linked immunosorbent assay (ELISA) were used to confirm the mass spectrometry 
identification and quantification data as described in the online data supplement.  
Statistical analyses 
SPSS was used for all statistical analysis unless otherwise stated. iTRAQ sample 
labels were used to calculate each protein’s abundance per sample relative to the 
reference included in each mass spectrometry run, thus enabling comparison of 
protein abundance between samples. Hierarchical clustering of sample protein 
profiles was performed by PermutMatrix [24] using Euclidean distance dissimilarity 
and McQuitty’s linkage criteria. Prior to cluster analysis proteins within the dataset 
were tested for collinearity (Bivariate Spearman correlation coefficient >0.9) and four 
proteins that correlated highly with others were subsequently excluded. Independent 
samples T-tests and Mann Whitney U tests were performed to identify differentially 
abundant proteins (p<0.05) between the CF and control cohorts. Ingenuity Pathway 
Analysis (IPA) was then employed to predict: (a) Canonical Pathway activity in both 
the CF and control consensus core proteomes (Fisher’s Exact Test); (b) altered Bio 
Function activity in CF relative to the control group (Fisher’s Exact Test); (c) Bio 
Function up- or down-regulation in CF (IPA Regulation z-score algorithm).  
For proteins detected in >80% of CF samples, their percentage abundance within 
each sample was estimated by the percentage exponentially modified Protein 
Abundance Index (% emPAI [25]) using MS Excel. For proteins of consistently high 
abundance (>1% emPAI) in CF, % emPAIs were compared between the CF and 
control cohorts (Mann-Whitney U test). 
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Bivariate Spearman correlation analysis and univariate analysis were performed to 
identify proteins whose % emPAIs correlated with FEV1 % predicted and to identify 
independent factors. A Benjamini-Hochberg multiple comparisons adjustment was 
performed for the correlation analysis (MS Excel) to control the false discovery rate 
at <0.05. For each of the proteins correlating negatively with FEV1, paired T-tests 
and Wilcoxon signed-ranks tests were performed to compare the relative abundance 
(sample:reference) of matched CF pre-treatment and <24h post-treatment samples 
to identify differential abundances associated with antibiotic treatment of 
exacerbation. Again, the false discovery rate was controlled at <0.05 by a Benjamini-
Hochberg multiple comparisons adjustment. 
 
RESULTS  
Core signature proteome in CF cohort 
In accordance with inclusion criteria, the CF cohort comprised adults with CF who 
were chronically infected with P. aeruginosa. The cohort’s variation in % FEV1 
predicted (26-102%) and collection of 3 sputum samples from each individual 
(covering clinical stability, exacerbation and following antibiotic treatment of 
exacerbation) prevented proteome bias towards any particular clinical status within 
this population. In total, 2210 human proteins were detected including 119 which 
were common to all 48 samples, including those from healthy controls. A further 38 
proteins were detected in all samples belonging to only one cohort suggesting low 
abundance or absence in the other cohort, although differential abundance between 
the two cohorts cannot be proven statistically. Twenty-one proteins were detected 
only in the CF cohort and 17 proteins were detected only in the control cohort. Table 
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E3 in the online data supplement records all proteins detected in all the samples 
belonging to at least one cohort.  
The heatmap in Figure 1, which clusters individual sputum samples according to 
relative abundance levels (sample:reference) of consistently detected proteins, 
shows that CF and control samples largely cluster separately. The two exceptions, 
CF3.2 and CF4.2 (marked with an arrow in Figure 1), are CF samples collected just 
after completion of antibiotic treatment for a pulmonary exacerbation.  
IPA Canonical Pathways in CF and control cohorts 
The 136 proteins detected in all control samples and the 140 proteins detected in all 
CF samples were treated as consensus core proteomes for the two cohorts. 
Qualitative individual analysis of these proteomes was performed by Ingenuity 
Pathway Analysis (IPA) to determine Canonical Pathways predicted by IPA as active 
in each cohort. Figure 2 shows the top 5 Pathways predicted in the control proteome 
and all Canonical Pathways predicted by to have a >5-fold increase in p-value in the 
CF proteome compared to the control proteome, indicating likely up-regulation in CF. 
Those predicted as most up-regulated in CF are involved in immune functions 
including neutrophil recruitment, rearrangement of the actin cytoskeleton, 
phagocytosis and T cell signaling.  
IPA Bio Function analysis of the CF differential proteome  
Comparison of relative abundance levels (sample:reference) between the two 
cohorts (36 CF samples versus 12 control samples) was performed for the 119 
proteins detected in all samples in order to identify cohort differences. 54 proteins 
were found to be less abundant and 36 more abundant in the CF versus control 
cohort (independent samples T-tests & Mann Whitney U tests, p<0.05; Table E3, 
online data supplement). Abundance ratios (CF:control) for all differentially abundant 
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proteins were included for IPA Bio Function analysis irrespective of the degree of 
difference. Table E4 (online supplement) records the Bio Functions predicted to be 
differentially expressed (Fisher’s Exact Test, p<0.05) in CF with Regulation z-scores 
>1 or <-1 (IPA Regulation z-score algorithm, p<0.05), and those predicted with a 
higher confidence level (p<0.0005), but with a less noteworthy or absent Regulation 
z-score (shaded rows).  
Inflammatory Response, Cellular Movement, Cell Death, Cellular Growth and 
Proliferation, and Free Radical Scavenging were predicted by IPA as most altered in 
CF compared to the control cohort, with regard to the extent of regulation 
(Regulation z-score). This is largely supported by the data in Table E5 (online data 
supplement), which records Gene Ontology (GO) biological process classifications 
for the 38 proteins detected consistently in only one cohort, and the 6 proteins 
identified by Mann-Whitney U test as showing differential abundance between the 
two cohorts.  
High abundance proteins in CF sputum cells 
As high abundance proteins have greater potential for directly impacting the lung 
environment, we identified proteins that were consistently detected at high 
abundance per sample in the CF cohort and determined if their abundance levels per 
sample differed significantly from those of the control cohort. Six proteins were found 
to each comprise >1% of total human cellular protein per sample (% emPAI) in >80% 
of CF samples. Comparison of the % emPAIs for these proteins between CF and 
control cohorts detected increased abundance of all six in CF (independent samples 
Mann-Whitney U test, p<0.01). Their median±IQR % emPAIs are displayed in Figure 
4 along with the corresponding data for the control cohort. The Human Protein Atlas 
[26] identifies all as being either highly or moderately expressed in bone marrow 
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hematopoietic cells (50% of which are myelopoietic cells) and all except cathepsin G 
as moderately or lowly expressed in lung macrophages. No statistically significant 
difference in relative abundance level (sample:reference) for these 6 proteins was 
detected when comparing paired CF pulmonary exacerbation samples before and 
<24h after antibiotic treatment (Wilcoxon signed-ranks test, p<0.05). 
Sputum cellular proteins correlate with lung function  
In order to identify any associations between specific proteins and lung function, the 
relative abundance levels (sample:reference) of the 337 proteins detected in >80% 
CF samples were tested for correlation with lung function as indicated by FEV1 % 
predicted. Negative correlations (Bivariate Spearman correlation analysis, p<0.01; 
false discovery rate <0.05) were identified for the 17 proteins listed in Table 2, 
implicating them as potential biomarkers of CF lung disease. Positive correlations 
were also identified, but as the focus of this analysis was to identify potentially 
injurious proteins only the negative correlations are presented here. Alpha-1-
antitrypsin and olfactomedin-4 were independent factors for FEV1 % predicted 
(univariate analysis, p<0.01).  
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UniProt 
Accession 
Description Gene name 
Spearman 
correlation 
(FEV1) 
Signif. 
(p-value) 
CF 
pre-
/post-
abx 
D3DSM0 Integrin beta-2 * ITGB2 -.751 0.00000 1.114 
P80723 Brain acid soluble protein 1 * BASP1 -.732 0.00000 1.343 
P02675 Fibrinogen beta chain ** FGB -.732 0.00000 1.690 
P01009 Alpha-1-antitrypsin SERPINA1 -.674 0.00001  
P30048 Thioredoxin-dependent peroxide 
reductase, mitochondrial 
PRDX3 -.646 0.00012 
 
J3QLC9 Haptoglobin * HP -.617 0.00028 1.288 
P08246 Neutrophil elastase ELANE -.608 0.00036  
Q08722 Leukocyte surface antigen CD47 
* 
CD47 -.608 0.00037 
1.115 
Q6UX06 Olfactomedin-4 ** OLFM4 -.601 0.00011 1.620 
P15144 Aminopeptidase N ANPEP -.540 0.00067  
F8VV56 CD63 antigen * CD63 -.586 0.00068 1.338 
C9JNR4 Transforming protein RhoA RHOA -.578 0.00082 1.354 
P01023 Alpha-2-macroglobulin A2M -.543 0.00192  
O95498 Vanin 2 * VNN2 -.540 0.00205 1.475 
O94804 Serine/threonine-protein kinase 
10 
STK10 -.535 0.00233 
 
E7ER45 Maltase-glucoamylase, intestinal 
** 
MGAM -.523 0.00106 
1.314 
P08473 Neprilysin MME -.511 0.00146  
 
Table 2: Correlation between relative abundance level (sample:reference) and lung 
function (FEV1 % predicted) for proteins present in >80% CF samples at false 
discovery rate <0.05. * and ** indicate proteins with significantly different abundance 
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levels (p<0.05 and p<0.01, respectively) in the CF cohort when comparing matched 
pre-antibiotic and <24h post-antibiotic treatment samples. Median ratios (pre- 
treatment : <24h post-treatment) are recorded in the final column. 
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Longitudinal analysis of antibiotic treatment of CF exacerbation  
Figure E1 (online data supplement) shows that total protein yield (mg per g sputum) 
consistently decreased for each CF participant following antibiotic treatment of 
exacerbation and that follow-up samples collected during clinical stability more 
closely resembled pre-treatment samples with respect to yield. Individual proteins 
identified as correlating negatively with FEV1 % predicted (n=17) or consistently at 
high abundance in CF (n=6) were analysed to compare the relative abundance 
(sample:reference) of matched CF pre-treatment and <24h post-treatment samples. 
As shown in Table 2, paired samples T-tests (including Benjamini-Hochberg multiple 
comparisons adjustment of false discovery rate adjustment to <0.05) identified 9 
proteins with decreased abundance (p<0.05) following treatment of pulmonary 
exacerbation. Figure 1 shows that for 7 of the 12 individuals with CF, samples 
collected during clinical stability (labelled “.3”) clustered more closely with the 
matched pre-treatment sample (“.1”) than the post-treatment sample (“.2”). 
ELISA validation of candidate biomarkers 
As high abundance proteins (Figure 4) have greater potential for directly impacting 
the lung environment, we chose to validate myeloperoxidase and lactotransferrin as 
candidate biomarkers. Quantification of our existing samples by commercial ELISA 
confirmed their consistently higher abundance in CF compared to healthy control 
sputum cells (p<0.05, Mann Whitney U test, Figure E2 in the online supplement). 
Additionally, this demonstrated that commercial ELISAs are a practical method for 
follow-up validation of candidate biomarkers in a larger independent cohort. 
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DISCUSSION  
In order to further elucidate the mechanisms of CF-associated tissue damage in 
adults with chronic respiratory P. aeruginosa infection, this study has for the first time 
specifically investigated the global proteome and functional activity of the combined 
population of cells present in CF sputum. As such, it uniquely studies the protein 
abundance of cells in vivo, thereby taking into account both their natural frequency in 
the sputum cell population and the effects of intercellular interactions. Thus, it 
delivers a high degree of clinical relevance to our findings. Moreover, to accurately 
characterise a consistent CF phenotype for adults chronically infected with P. 
aeruginosa and avoid bias due to patient individuality, we considered only those 
proteins detected in all samples within the CF and healthy control cohorts. Thus, our 
study is more stringent than previously published proteomic studies that either 
included proteins detected at high frequency in at least one sample [18] or used 
pooled samples [14-16]. 
In agreement with previous investigations of CF sputum or BAL [14, 15, 17, 18], we 
found the CF proteome to be largely distinct from that of the control cohort. IPA 
predicted that Canonical Pathways which affect or involve actin cytoskeleton 
rearrangement directed by the Rho family small GTPases, including RhoA, Rac1 and 
Cdc42 were over-represented in the CF samples. Thus, our in vivo data confirms 
previous in vitro observations linking CFTR deficiency with increased RhoA 
expression [27, 28]. This may be significant for CF lung health as impaired 
efferocytosis (phagocytosis of apoptotic cells) [29] and reduced expression of iNOS 
[28] resulting from CFTR deficiency have been reported as mediated by RhoA up-
regulation. 
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Similarly to previous proteomics studies of cell-free CF sputum/BAL, GO and IPA Bio 
Function analyses identified up-regulation of the immune and inflammatory response 
[14-18]. In particular, we found increased immune cell movement and activation, and 
generation of reactive oxygen species. These observations fit with existing 
knowledge about the CF phenotype which is typified by chronic inflammation and 
neutrophilia. Interestingly, an IPA predicted network identified lipopolysaccharide as 
a likely trigger of inflammation. Cell death, growth and proliferation were also 
predicted as dysregulated in CF, in such a way that both death and proliferation of 
immune cells were decreased, while both were increased in non-immune cells. 
These observations further support the growing understanding of the CF phenotype. 
Tissue damage and cell death is rampant, while excessive proliferation of respiratory 
epithelial cells leading to squamous cell metaplasia and dysplasia is common in CF 
[30, 31]. Delayed neutrophil apoptosis and clearance is thought to contribute to 
chronic inflammation [2] and our study detected CF-associated differential 
abundance of matrix metalloproteinase 8, annexin I and nicotinamide 
phosphoribosyltransferase, which have been implicated in delayed apoptosis and 
clearing of inflammatory and immune cells in vitro [32] and in vivo [33, 34].  
Compositional breakdown analysis of sample proteomes found S100-A9, the histone 
H2B family, lactotransferrin, histone H4, cathepsin G and myeloperoxidase to be 
consistently present in high abundance in CF and to each be significantly more 
abundant in the CF cohort than the control cohort. Importantly, all six proteins are 
known constituents of neutrophil extracellular trap (NET) structures, the release of 
which by neutrophils exerts antimicrobial activity through the degradation of virulence 
factors, bacterial killing and antifungal activity [35-37].  
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As our study focused on sputum cellular proteins we did not look specifically for NET 
structures, which are extracellular, and therefore do not know if they were present. 
However, NETs have been found previously in the CF airways fluid and the 
abundance of free DNA that is characteristic of NETs correlated with obstructive lung 
function [38]. As well as killing microbes, NETs have been found to directly induce 
human alveolar epithelial and endothelial cell death, with the predominant cytotoxic 
effect being attributed to histones and myeloperoxidase [39].   
Individually, these six high abundance proteins may also have significance for CF 
lung pathology and several have previously been reported as up-regulated in CF 
sputum and/or BALF [14, 15, 18]. Importantly, differential abundance of 
myeloperoxidase in CF sputum fluid has been correlated with FEV1 % predicted [17], 
and myeloperoxidase and calgranulin B have been identified in sputum fluid as CF-
associated autoantigens [16]. Cathepsin G has been implicated in degradation of 
surfactant protein A, so reducing the innate pulmonary antimicrobial defence [40], 
while S100-A9 has been shown to induce MUC5AC production in human bronchial 
epithelial cells cultured in vitro, suggesting a potential contribution to pathological 
mucin hyperproduction in vivo [41]. In a study investigating trauma-induced lung 
injury, Abrams et al. reported that histones induced NET formation and 
myeloperoxidase release in vitro, while histone infusion in mouse models resulted in 
lung structural damage and neutrophil congestion [42]. Additionally, extracellular 
histones H4 and H3.3 have been implicated in asthma-related inflammation and 
remodeling, and in chronic obstructive pulmonary disease (COPD), respectively [43, 
44]. Consequently, our consistent detection of these proteins in such high 
abundance in the sputum cellular fraction identifies a potential risk to lung health, 
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either through their active secretion and NET formation or following passive release 
into the sputum fluid via cell death. 
A number of proteins detected consistently in CF sputum correlated negatively with 
lung function measured as FEV1 % predicted. Their biological/clinical relevance and 
potential for causing injury are discussed more fully in the online supplement. 
Longitudinal analysis of patient-matched CF samples showed differential 
abundances for 10 out of these 17 proteins in the CF cohort following intravenous 
antibiotic treatment of a pulmonary exacerbation. Interestingly, all the changes in 
abundance resulted in levels closer to those in the control cohort. Previously, Sloane 
et al [17] observed that for 4/13 adults with CF, their cell-free sputum proteome 
profiles moved closer to those of healthy controls following antibiotic treatment of an 
exacerbation. However, the latter observations were made by comparison of 2-D gel 
images rather than implicating and identifying particular proteins. We also found that, 
although sputum total protein yield decreased in the CF cohort by completion of 
antibiotic treatment, it had reverted to pre-treatment levels by the clinically stable 
follow-up time point. This suggests that proteomic changes associated with antibiotic 
treatment may be temporary. 
Overall, the proteins detected as negatively correlating with FEV1 suggest that the 
degree of inflammation, neutrophil influx, protease activity and airway remodeling 
may all contribute to defining lung function. Alpha-1-antitrypsin and olfactomedin-4 
were identified as independent factors negatively correlating with FEV1  although this 
does not demonstrate causation of harm.  Acute inflammation-associated protein 
alpha-1-antitrypsin has previously been identified as a biomarker of pulmonary 
disease in CF which can be predictive of response to treatment and prognosis [45]. 
As an inhibitor of neutrophil serine proteases, which contribute significantly to lung 
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destruction in CF, its negative correlation with lung function might seem surprising. 
However, previous studies observed that plasma deficiencies during inflammation 
were associated with less severe lung disease in CF [46]. No association between 
olfactomedin-4 and CF lung health has previously been reported. However, 
olfactomedin-4 has been shown to down-regulate proinflammatory responses to 
bacterial infection and reduce bacterial killing mediated by granule serine 
proteinases [47, 48], which could have the potential to negatively affect lung health.  
There are a number of limitations to our study. As is typical for untargeted 
exploratory proteomic studies, we used highly sensitive shotgun technologies to 
obtain quantitative, high proteome coverage analysis of sputum cells as a novel 
target. The trade-off for such in-depth analysis is a relatively low sample size. Given 
the sample numbers practicable, we maximised power by restricting the study to 
adults with CF chronically infected with P. aeruginosa, who experienced pulmonary 
exacerbation requiring hospitalization for treatment with intravenous antibiotics. 
While CF sputum proteome responses to other microbial infections may vary, we 
considered this cohort most informative as 57% of the adult CF population is 
chronically infected with P. aeruginosa [49]. As this study investigated only adults the 
findings cannot be extended to children or individuals not chronically infected with P 
aeruginosa. Although proteins reported as potentially damaging were detected as 
consistently abundant or correlating negatively with lung function in our study, this is 
not proof of causation of lung injury. Additionally, the limited sample size requires 
that any potential significance as biomarkers either of lung function or disease 
severity warrants validation in a larger independent cohort. As an intial stage in this 
validation process we used commercial ELISAs to confirm findings in our existing 
cohort for myeloperoxidase and lactotransferrin. Both proteins were considered as 
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candidate biomarkers due to their consistently high abundance in CF sputum, 
increased abundance in the CF compared to the control cohort and previous 
associations in the literature with potential for lung damage. Thus, we demonstrated 
that commercial ELISAs are a practical method for follow-up validation in an 
independent cohort. However, while cohort size and characteristics limit the scope of 
our study conclusions, the findings are of exploratory interest and may have future 
clinical value within a defined commonly encountered CF cohort.  Moreover, the 
investigation of all types of cells in the proportions occurring naturally in sputum is 
novel and the approach adopted in our study could be informative for other 
respiratory conditions. 
In summary, within the cohort studied, i.e. adults with chronic P. aeruginosa 
infection, we have detected a distinct signature for the CF sputum cellular proteome, 
and have used pathway and functional analyses to predict its potential clinical 
impact.  In particular, our data highlight the prevalence and predominance of proteins 
that can be associated with NET structures and have been reported as linked to 
tissue damage. Additionally, we identified a number of proteins that correlate 
negatively with lung function, many of which have previously been associated with 
lung injury. Overall, these findings expand the current understanding of the 
mechanisms behind P. aeruginosa associated CF lung disease in adults and identify 
sputum cell proteins as candidate biomarkers for disease status, prognostic 
indicators or as stratification parameters for treatment prescription. 
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Figure 1: Distribution and relative abundance of human proteins detected in sputum 
samples collected from CF and healthy control cohorts. A. shows that 119 proteins 
were found in all 48 samples, i.e. both CF and control, while a further 21 proteins 
were found exclusively in all CF samples and 17 proteins exclusively in all control 
samples. B. shows hierarchical clustering (using Euclidean distance dissimilarity and 
McQuitty’s linkage criteria) of individual sputum samples according to the relative 
abundance levels for all 119 consistently detected proteins. CF and control samples 
largely cluster separately with the only exceptions being 2 CF samples (marked with 
black arrows) collected after antibiotic treatment for pulmonary exacerbation. The 
scale is a log2 ratio of relative abundance.   
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Figure 2: Differential activity of Canonical Pathways in consensus CF and control 
proteomes.  Based on the set of proteins detected in all samples within a cohort, 
Ingenuity Pathway Analysis software applied Fisher’s Exact Test to predict the 
Canonical Pathways likely to be active within that cohort (p<0.05). The top 5 
pathways predicted in the control cohort concern general metabolism, clatherin-
mediated endocytosis signaling and mitochondrial dysfunction and these were 
detected with approximately equal probabilities in both cohorts. Pathways where 
there is a >5-fold increase in p-value in the CF proteome compared to the control 
proteome, indicating likely up-regulation in CF are involved in immune functions 
including neutrophil recruitment, rearrangement of the actin cytoskeleton, 
phagocytosis and T cell signaling.  
 
  
 33 
 
 
Figure 3: Ingenuity Pathway Analysis predicted network for proteins detected in CF 
involved in Inflammatory Response and Cell Movement Bio Functions. The intensity 
of red or green shading indicates the degree of increased or decreased abundance 
in CF relative to healthy controls, respectively. A red outline with no internal shading 
indicates that the protein was detected exclusively in the CF cohort. The network 
identifies lipopolysaccharide (LPS) as a likely inflammatory trigger. 
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Figure 4: Percentage abundance estimates (% emPAI median ± IQR) for proteins 
comprising >1% of total human proteins in >80% of CF samples. Human Protein 
Atlas (26) annotations for protein expression in terms of tissue location and localised 
abundance are recorded. H, M and L indicate high, medium and low protein 
expression. All proteins are either highly or moderately expressed in bone marrow 
hematopoietic cells, 50% of which are myelopoietic cells, and all except cathepsin G 
are moderately or lowly expressed in lung macrophages. 
 
